Evidence map›Paper›PMID 39054420›Full record

Observational studyBMC primary care2024

Characteristics of the phenotypes in prevalent and incident cases of heart failure in primary care: IBERICAN study.

Sergio Cinza-Sanjurjo, Miguel Ángel Prieto-Díaz, Vicente Pallarés-Carratalá, Rafael M Micó-Pérez, Sonsoles Velilla-Zancada, Alfonso Barquilla-García, Leovigildo Ginel-Mendoza, Antonio Segura-Fragoso, Vicente Martín-Sánchez, José Polo-García

Registry-linked trialAbstract readObservational Study
In one paragraph

Observational study in BMC primary care, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02261441 (Identificación de la poBlación Española de RIesgo CArdiovascular y reNal), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02261441 unknown statusnot on this map

Identificación de la poBlación Española de RIesgo CArdiovascular y reNal

TypeobservationalSponsorLa Sociedad Española de Médicos de Atención PrimariaRan2014 to 2019Enrolled15,000ConditionsCardiovascular DiseaseArmsObservational and noninterventional study
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sergio Cinza-SanjurjoCS Milladoiro, Área Sanitaria Integrada Santiago de Compostela, Travesía do Porto, Ames, 15895, PC, Spain. sergio.cinza@usc.es.
Miguel Ángel Prieto-DíazVallobín-La Florida Health Centre, Oviedo, Spain.
Vicente Pallarés-CarrataláDepartment of Medicine, Jaume I University, Castellon, Spain.
Rafael M Micó-PérezFontanars dels Alforins Health Centre, Xàtiva-Ontinyent Department of Health, Valencia, Spain.
Sonsoles Velilla-ZancadaJoaquin Elizalde Health Centre, Logroño, La Rioja, Spain.
Alfonso Barquilla-GarcíaTrujillo Health Center, Cáceres, Spain.
Leovigildo Ginel-MendozaCiudad Jardín Health Center, Málaga, Spain.
Antonio Segura-FragosoEpidemiology Unit, Semergen Research Agency, Madrid, Spain.
Vicente Martín-SánchezGene-Environment-Health Interaction Research Group (GIIGAS), University of León, Leon, Spain.
José Polo-GarcíaCasar de Cáceres Health Centre, Cáceres, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe management in primary care (PC) of the patients with Heart Failure (HF) is different from the management hospital, in a special way compared to cardiology departments.

objectiveTo define the characteristics in both phenotypes of HF in prevalent and incident cases of HF in patients recruited in a large PC sample.

methodsWe proposed a and longitudinal analyses, in patients of the IBERICAN cohort, that recruited 8,066 patients in the Spanish primary care system, with 15,488 patients-years of follow-up. Of them, 252 patients (3.1%) had diagnoses of HF. HF was classified according to the 2014 guidelines in two groups: HF with a reduced eject fraction or HFrEF (LVEF < 50%) and HF with preserved eject fraction or HFpEF (LVEF ≥ 50%). Recommended treatment was defined as the patient receiving drug treatment with Renin-Angiotensin-System (RAS) blockers with beta-blockers and, optionally, spironolactone. The incidence of new cases of HF was calculated in the 7,814 patients without HF in the inclusion visit. Finally, we analysed which variables associated the onset new cases and get the hazard ratio (HR) with the confidence interval at 95% ([95%CI]). Clinical trials register: NCT02261441 (02/05/2017).

resultsThe HFpEF was the most frequent phenotype in prevalent cases (61.1%) and incident cases (73.9%). Patients with HFrEF had a higher prevalence of coronary heart disease (p = 0.008) and PAD (p = 0.028), and no statistically significant differences was observed in the therapeutic groups used between both groups. The incidence of HF was 12.8 cases/1000 inhabitants/year, 35.6% of them was diagnosed in PC. The renin-angiotensin system blockers were more used in PC (60%) and beta-blockers (100%) and spironolactone (60%) in hospital. The female sex showed a protective effect for incident cases (0.51 [0.28-0.92]); and AF (HR [95%CI]: 2.90 [1.51-5.54]), coronary heart disease (HR [95%CI]: 2.18 [1.19-4.00]) and hypertension (HR [95%CI]: 1.91 [1.00-3.64]) increased the risk of developing HF.

conclusionsHF phenotype more frequent and incident in PC was the HFpEF, but only one third of them are diagnosed in PC level. The female sex showed a protective effect and atrial fibrillation, ischaemic heart disease and hypertension increased the risk of develop HF.

Indexed as

Heart FailurePhenotypePrimary Health CareAdrenergic beta-AntagonistsAgedAged, 80 and overFemaleHumansIncidenceLongitudinal StudiesMaleMiddle AgedPrevalenceSpainSpironolactoneStroke VolumeAdrenergic beta-AntagonistsSpironolactoneDiagnosisHeart failureIncidencePrimary care prevalence

Identifiers

PMID39054420
PMCPMC11270967

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.